{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:45:51Z","timestamp":1792273551446,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna","id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00198-026-08040-3","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:24:59Z","timestamp":1777501499000},"page":"2005-2016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative denosumab exposure and risk of revision after total hip and knee arthroplasty in osteoarthritis: a registry-based data linkage study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-7351","authenticated-orcid":false,"given":"Jacopo","family":"Ciaffi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gherardo","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Faldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"8040_CR1","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","volume":"5","author":"JD Steinmetz","year":"2023","unstructured":"Steinmetz JD, Culbreth GT, Haile LM et al (2023) Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol 5:e508\u2013e522","journal-title":"Lancet Rheumatol"},{"key":"8040_CR2","doi-asserted-by":"publisher","first-page":"8305","DOI":"10.1038\/s41598-025-93124-z","volume":"15","author":"R Wu","year":"2025","unstructured":"Wu R, Guo Y, Chen Y et al (2025) Osteoarthritis burden and inequality from 1990 to 2021: a systematic analysis for the global burden of disease Study 2021. Sci Rep 15:8305","journal-title":"Sci Rep"},{"key":"8040_CR3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3899\/jrheum.170990","volume":"46","author":"JA Singh","year":"2019","unstructured":"Singh JA, Yu S, Chen L et al (2019) Rates of total joint replacement in the United States: future projections to 2020\u20132040 using the National Inpatient Sample. J Rheumatol 46:1134\u20131140","journal-title":"J Rheumatol"},{"key":"8040_CR4","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.arth.2020.02.030","volume":"35","author":"AM Schwartz","year":"2020","unstructured":"Schwartz AM, Farley KX, Guild GN et al (2020) Projections and epidemiology of revision hip and knee arthroplasty in the United States to 2030. J Arthroplasty 35:S79-85","journal-title":"J Arthroplasty"},{"key":"8040_CR5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/EOR-23-0080","volume":"9","author":"C Clar","year":"2024","unstructured":"Clar C, Leitner L, Koutp A et al (2024) The worldwide survival rate of total hip arthroplasties is improving: a systematic comparative analysis using worldwide hip arthroplasty registers. EFORT Open Rev 9:745\u201350","journal-title":"EFORT Open Rev"},{"key":"8040_CR6","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1002\/ksa.12225","volume":"32","author":"F Pardo","year":"2024","unstructured":"Pardo F, Bordini B, Salerno M et al (2024) Total knee arthroplasty survival rates are lower in younger men, as well as rheumatoid patients and after previous high\u2010tibial osteotomy: a registry study. Knee Surg Sports Traumatol Arthrosc 32:2573\u201380","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"8040_CR7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jor.23003","volume":"34","author":"C Huang","year":"2016","unstructured":"Huang C, Jiang C, Hsieh C et al (2016) Local bone quality affects the outcome of prosthetic total knee arthroplasty. J Orthop Res 34:240\u2013248","journal-title":"J Orthop Res"},{"key":"8040_CR8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5371\/hp.2021.33.2.53","volume":"33","author":"S-W Lee","year":"2021","unstructured":"Lee S-W, Kim W-Y, Song J-H et al (2021) Factors affecting periprosthetic bone loss after hip arthroplasty. Hip & Pelvis 33:53\u201361","journal-title":"Hip & Pelvis"},{"key":"8040_CR9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/jor.25642","volume":"42","author":"N Soltanihafshejani","year":"2024","unstructured":"Soltanihafshejani N, Bitter T, Verdonschot N et al (2024) The effect of periprosthetic bone loss on the failure risk of tibial total knee arthroplasty. J Orthop Res 42:90\u201399","journal-title":"J Orthop Res"},{"key":"8040_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-01055-9","volume":"17","author":"P-L Xiao","year":"2022","unstructured":"Xiao P-L, Hsu C-J, Ma Y-G et al (2022) Prevalence and treatment rate of osteoporosis in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis. Arch Osteoporos 17:16","journal-title":"Arch Osteoporos"},{"key":"8040_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22540\/JRPMS-05-001","volume":"05","author":"I Pitropakis","year":"2021","unstructured":"Postgraduate Program \u201cMetabolic Bone Diseases\u201d, National and Kapodistrian University of Athens, Medical School, Athens, Greece, Pitropakis I (2021) The action of anti-resorptive drugs on the survival of total knee and hip arthroplasty. JRPMS 05:1\u20137","journal-title":"JRPMS"},{"key":"8040_CR12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032\u20131045","journal-title":"Mayo Clin Proc"},{"key":"8040_CR13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677\u2013692","journal-title":"Bone"},{"key":"8040_CR14","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"8040_CR15","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP et al (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10:152","journal-title":"J Clin Med"},{"key":"8040_CR16","doi-asserted-by":"crossref","first-page":"d7222","DOI":"10.1136\/bmj.d7222","volume":"343","author":"D Prieto-Alhambra","year":"2011","unstructured":"Prieto-Alhambra D, Javaid MK, Judge A et al (2011) Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ 343:d7222\u2013d7222","journal-title":"BMJ"},{"key":"8040_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s42836-021-00068-6","volume":"3","author":"J Xu","year":"2021","unstructured":"Xu J, Li H, Qu Y et al (2021) Denosumab might prevent periprosthetic bone loss after total hip and knee arthroplasties: a review. Arthroplasty 3:13","journal-title":"Arthroplasty"},{"key":"8040_CR18","volume":"10","author":"S Teng","year":"2015","unstructured":"Teng S, Yi C, Krettek C et al (2015) Bisphosphonate use and risk of implant revision after total hip\/knee arthroplasty: a meta-analysis of observational studies. PLoS ONE 10:e0139927","journal-title":"PLoS ONE"},{"key":"8040_CR19","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1007\/s11999-015-4263-4","volume":"473","author":"M Khatod","year":"2015","unstructured":"Khatod M, Inacio MCS, Dell RM et al (2015) Association of bisphosphonate use and risk of revision after THA: outcomes from a US total joint replacement registry. Clin Orthop Relat Res 473:3412\u20133420","journal-title":"Clin Orthop Relat Res"},{"key":"8040_CR20","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1002\/art.38789","volume":"66","author":"D Prieto\u2010Alhambra","year":"2014","unstructured":"Prieto\u2010Alhambra D, Lalmohamed A, Abrahamsen B et al (2014) Oral bisphosphonate use and total knee\/hip implant survival: validation of results in an external population\u2010based cohort. Arthritis Rheumatol 66:3233\u20133240","journal-title":"Arthritis Rheumatol"},{"key":"8040_CR21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2340\/17453674.2022.4537","volume":"93","author":"D Kiritopoulos","year":"2022","unstructured":"Kiritopoulos D, Nystr\u00f6m A, Ullmark G et al (2022) Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial. Acta Orthop 93:709\u2013720","journal-title":"Acta Orthop"},{"key":"8040_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00774-023-01405-2","volume":"41","author":"N Nakura","year":"2023","unstructured":"Nakura N, Hirakawa K, Takayanagi S et al (2023) Denosumab prevented periprosthetic bone resorption better than risedronate after total hip arthroplasty. J Bone Miner Metab 41:239\u201347","journal-title":"J Bone Miner Metab"},{"key":"8040_CR23","volume":"3","author":"HT Aro","year":"2019","unstructured":"Aro HT, Nazari-Farsani S, Vuopio M et al (2019) Effect of denosumab on femoral periprosthetic BMD and early femoral stem subsidence in postmenopausal women undergoing cementless total hip arthroplasty. JBMR Plus 3:e10217","journal-title":"JBMR Plus"},{"key":"8040_CR24","volume":"16","author":"A D\u2019Amuri","year":"2025","unstructured":"D\u2019Amuri A, Bordini B, Pagani M et al (2025) Statins and long-term risk of revision surgery after total hip arthroplasty in osteoarthritis: a multi-source data linkage study. Front Pharmacol 16:1492200","journal-title":"Front Pharmacol"},{"key":"8040_CR25","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.knee.2014.02.012","volume":"21","author":"B Bordini","year":"2014","unstructured":"Bordini B, Stea S, Falcioni S et al (2014) Unicompartmental knee arthroplasty. Knee 21:1275\u20131279","journal-title":"Knee"},{"key":"8040_CR26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00198-024-07191-5","volume":"35","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Yang Y, Wang J et al (2024) The Healing and therapeutic effects of perioperative bisphosphonate use in patients with fragility fractures: meta-analysis of 19 clinical trials. Osteoporos Int 35:1897\u2013907","journal-title":"Osteoporos Int"},{"key":"8040_CR27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"8040_CR28","first-page":"14","volume":"81","author":"General Assembly of the World Medical Association","year":"2014","unstructured":"General Assembly of the World Medical Association (2014) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 81:14\u20138","journal-title":"J Am Coll Dent"},{"key":"8040_CR29","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1002\/ksa.12678","volume":"33","author":"P Sadoghi","year":"2025","unstructured":"Sadoghi P, Koutp A, Prieto DP et al (2025) The projected economic burden and complications of revision hip and knee arthroplasties: Insights from national registry studies. Knee Surg Sports Traumatol Arthrosc 33:3211\u20137","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"8040_CR30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jbmr.3883","volume":"35","author":"A Nystr\u00f6m","year":"2020","unstructured":"Nystr\u00f6m A, Kiritopoulos D, Ullmark G et al (2020) Denosumab prevents early periprosthetic bone loss after uncemented total hip arthroplasty: results from a Randomized Placebo-Controlled Clinical Trial. J Bone Miner Res 35:239\u2013247","journal-title":"J Bone Miner Res"},{"key":"8040_CR31","doi-asserted-by":"crossref","DOI":"10.1002\/jeo2.70350","volume":"12","author":"G Senesi","year":"2025","unstructured":"Senesi G, Barone G, Pinelli S et al (2025) The relationship between stress shielding, bone density changes and implant migration, failure and fracture after total knee arthroplasty: A systematic review. J Exp Orthop 12:e70350","journal-title":"J Exp Orthop"},{"key":"8040_CR32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2106\/JBJS.20.01454","volume":"103","author":"KT Van Hamersveld","year":"2021","unstructured":"Van Hamersveld KT, Marang-van De Mheen PJ, Tsonaka R et al (2021) Risk factors for tibial component loosening: a meta-analysis of long-term follow-up radiostereometric analysis data. Journal of Bone and Joint Surgery 103:1115\u201324","journal-title":"Journal of Bone and Joint Surgery"},{"key":"8040_CR33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/17453674.2017.1300746","volume":"88","author":"H Ledin","year":"2017","unstructured":"Ledin H, Good L, Aspenberg P (2017) Denosumab reduces early migration in total knee replacement. Acta Orthop 88:255\u2013258","journal-title":"Acta Orthop"},{"key":"8040_CR34","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.knee.2019.12.010","volume":"27","author":"Y Murahashi","year":"2020","unstructured":"Murahashi Y, Teramoto A, Jimbo S et al (2020) Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty. Knee 27:580\u2013586","journal-title":"Knee"},{"key":"8040_CR35","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz322","volume":"105","author":"T Diker-Cohen","year":"2020","unstructured":"Diker-Cohen T, Rosenberg D, Avni T et al (2020) Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab 105:dgz322","journal-title":"J Clin Endocrinol Metab"},{"key":"8040_CR36","doi-asserted-by":"crossref","first-page":"1310262","DOI":"10.3389\/fimmu.2023.1310262","volume":"14","author":"I Panez-Toro","year":"2023","unstructured":"Panez-Toro I, Heymann D, Gouin F et al (2023) Roles of inflammatory cell infiltrate in periprosthetic osteolysis. Front Immunol 14:1310262","journal-title":"Front Immunol"},{"key":"8040_CR37","unstructured":"May T, Marappa-Ganeshan R. (2023) Stress Fractures. StatPearls. StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554538\/. Accessed 24 Oct 2025"},{"key":"8040_CR38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bone.2011.06.027","volume":"49","author":"P Peris","year":"2011","unstructured":"Peris P, Torra M, Olivares V et al (2011) Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49:706\u2013709","journal-title":"Bone"},{"key":"8040_CR39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.artd.2022.02.003","volume":"14","author":"CL McDonald","year":"2022","unstructured":"McDonald CL, Lemme NJ, Testa EJ et al (2022) Bisphosphonates in total joint arthroplasty: a review of their use and complications. Arthroplasty Today 14:133\u20139","journal-title":"Arthroplasty Today"},{"key":"8040_CR40","volume":"8","author":"N Zhang","year":"2020","unstructured":"Zhang N, Zhang Z-K, Yu Y et al (2020) Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy. Front Cell Dev Biol 8:325","journal-title":"Front Cell Dev Biol"},{"key":"8040_CR41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clinbiomech.2005.08.009","volume":"21","author":"T-C Yu","year":"2006","unstructured":"Yu T-C, Huang C-H, Hsieh C-H et al (2006) Fatigue resistance analysis of tibial baseplate in total knee prosthesis\u2014an in vitro biomechanical study. Clin Biomech 21:147\u2013151","journal-title":"Clin Biomech"},{"key":"8040_CR42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jor.20469","volume":"26","author":"D Delos","year":"2008","unstructured":"Delos D, Yang X, Ricciardi BF et al (2008) The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J Orthop Res 26:153\u2013164","journal-title":"J Orthop Res"},{"key":"8040_CR43","doi-asserted-by":"crossref","DOI":"10.1177\/21514593221116413","volume":"13","author":"E Chang","year":"2022","unstructured":"Chang E, Nickel B, Binkley N et al (2022) A novel osteoporosis screening protocol to identify orthopedic surgery patients for preoperative bone health optimization. Geriatr Orthop Surg Rehabil 13:21514593221116413","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"8040_CR44","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.arth.2019.03.044","volume":"34","author":"JT Bernatz","year":"2019","unstructured":"Bernatz JT, Brooks AE, Squire MW et al (2019) Osteoporosis is common and undertreated prior to total joint arthroplasty. J Arthroplasty 34:1347\u20131353","journal-title":"J Arthroplasty"},{"key":"8040_CR45","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.arth.2023.05.027","volume":"38","author":"S Jeong","year":"2023","unstructured":"Jeong S, Lee JW, Boucher HR (2023) The effect of preoperative bisphosphonate use on total hip arthroplasty outcomes. J Arthroplasty 38:2393-2397.e2","journal-title":"J Arthroplasty"},{"key":"8040_CR46","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.arth.2023.11.036","volume":"39","author":"A Lee","year":"2024","unstructured":"Lee A, Durst CR, Rajaee SS (2024) Initiation of bisphosphonates prior to total joint arthroplasty does not lower periprosthetic fracture risk. J Arthroplasty 39:1459\u20131462","journal-title":"J Arthroplasty"},{"key":"8040_CR47","volume":"23","author":"N Ong","year":"2021","unstructured":"Ong N, Zailan I, Tandon A (2021) Imaging update in arthroplasty. J Clin Orthop Trauma 23:101649","journal-title":"J Clin Orthop Trauma"},{"key":"8040_CR48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/jfb16050179","volume":"16","author":"C Morano","year":"2025","unstructured":"Morano C, Garofalo S, Bertuccio P et al (2025) A comprehensive literature review of total hip arthroplasty (THA): part 1\u2014biomaterials. JFB 16:179","journal-title":"JFB"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08040-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08040-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08040-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:07:34Z","timestamp":1792271254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08040-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8040"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08040-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C. reports payment or honoraria for lectures from Amgen, IBSA and Novartis, and support for attending meetings from AbbVie, Alfasigma and UCB. F.U. reports payment or honoraria for lectures from AbbVie, Novartis, Pfizer and Alfasigma, and support for attending meetings from AbbVie, Novartis, Pfizer, Alfasigma and UCB. R.C. reports payment or honoraria for lectures from AbbVie, Alfasigma, BMS, Lilly, Novartis, UCB, GSK, AstraZeneca and Boehringer Ingelheim. G.M. reports consulting fees from Sanofi, Sandoz and Merck, and lecture fees from UCB and Theramex. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}